Steven Moore

-

Extramural

-

PLCO (Learn more about this study)

2013-0255

Nov 11, 2013

Blood metabolite profiles and risk of developing breast cancer in PLCO.

Breast cancer risk is likely influenced by metabolic factors, but scientific knowledge on the subject is limited. Extensive pilot work by our group indicates that metabolomics is a reliable, robust, and potentially powerful tool for characterizing individual metabolic profiles. Herein, we propose a metabolomics analysis of ~600 metabolites in T1 serum samples from 550 postmenopausal breast cancer cases and 550 matched controls in PLCO not on menopausal hormone therapy at baseline. The study proposed is the second stage for our breast cancer metabolomics workwe have already conducted a metabolomics breast cancer study in postmenopausal women not on menopausal hormone therapy in the Shanghai Womens Health Study (SWHS: 333 cases, 333 controls; results enclosed). The proposed PLCO study will greatly enhance our statistical power to detect associations and will enable us to determine whether associations observed in an Asian population extend to a Western population and vice versa. We also propose to examine metabolic early markers of breast cancer in 200 of these cases by analyzing metabolic changes in serum samples collected proximal to disease, i.e. within the 3-36 months prior to diagnosis. We will compare changes in metabolite levels to changes in ~200 controls, using additional control samples collected at a similar point in follow-up. Analyses will be done using the liquid chromatography and gas chromatography mass spectrometry platforms of Metabolon Inc.

1. Examine each of ~600 identified metabolites and associated metabolic profiles in prediagnostic T1 serum in relation to subsequent breast cancer incidence

2. Examine metabolite levels and metabolic profiles in samples proximal to diagnosis in relation to breast cancer incidence